<DOC>
	<DOCNO>NCT01788462</DOCNO>
	<brief_summary>Sleep-disordered breathing characterize primarily partial total upper airway obstruction sleep . The common form sleep-disordered breathing obstructive sleep apnea ( OSA ) due recurrent collapse upper airway onset sleep state . The major risk factor associate development sleep apnea obesity male sex . The investigator also find high prevalence OSA HIV infect men woman , particularly among central lipohypertrophy , common find HIV-infected person receive antiretroviral therapy . Currently , overall hypothesis visceral adiposity , see HIV-infected person central lipohypertrophy , alters mechanical property compensatory neuromuscular response lead upper airway obstruction . Based recent finding non-HIV population , investigator demonstrate obesity associate elevation upper airway load ( passive Pcrit ) counterbalance compensatory upper airway neural response . Moreover , investigator find female sex , peripheral adiposity , young age associate increase compensatory neuromuscular response , male sex , central adiposity , old age associate blunt compensatory response . The loss compensatory neuromuscular response lead obstructive sleep apnea . Among HIV-infected patient central lipohypertrophy , tesamorelin ( Egrifta ) , growth hormone release hormone ( GHRH ) analogue , approve reduction visceral adipose tissue . The investigator hypothesize tesamorelin therapy reverse mechanical neurocompensatory alteration associate increased central obesity . In project investigator determine whether tesamorelin affect sleep apnea severity compensatory neuromuscular response upper airway sleep breathe men woman HIV infection . The proposed study design elucidate pathophysiologic basis development obstructive sleep apnea population . The study also provide insight neurohumoral regulation upper airway function , potentially new approach treatment sleep-disordered breathing .</brief_summary>
	<brief_title>Egrifta Replacement Sleep Disordered Breathing</brief_title>
	<detailed_description />
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>1 . Consenting adult document HIVinfection , age 18 75 year old 2 . Central lipohypertrophy determine clinician 3 . Not currently Egrifta ( tesamorelin ) therapy . 1 . Unstable cardiovascular disease ( decompensated CHF , myocardial infarction past 3 month , revascularization procedure past 3 month , unstable arrhythmia ) ; 2 . Uncontrolled hypertension ( BP &gt; 190/110 ) ; 3 . Presence cor pulmonale 4 . History end stage renal disease ( dialysis ) ; 5 . History end stage liver disease ( e.g . jaundice , ascites , history recurrent gastrointestinal bleeding , transjugular intrahepatic portosystemic shunt ( TIPS ) ; 6 . Bleeding disorder coumadin use ; 7 . Tracheostomy 8 . Active malignancy 9 . Pregnancy and/or nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tesamorelin</keyword>
	<keyword>Egrifta</keyword>
	<keyword>HIV</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Sleep Apnea</keyword>
</DOC>